Abstract: sensitive, simple, selective and accurate HPLC method was developed and validated for Simultaneousanalysis of antiviral drugs, Sofosbuvir, Daclatasvir and Ribavirinthat allowreduction in treatment duration for HCV patients that in turn decrease the cost of the treatment. The chromatographic separation achieved by isocratic elution on a reversed-phase analytical column [Hypersilgold® C18 (10μm, 150 x 4.6 mm) column] at ambient temperature. The mobile phase was a mixture of Methanol, Waterand Acetonitrile in ratio of 25:30:45 (v/v/v), injection volume was 20μl. and flow rate was 1ml/ minute, detectionwavelength was 243nm. The developed method was validated as per ICH........
Keywords: Daclatasvir, HPLC, Ribavirin, Sofosbuvir, Tablets
[1]. NahlaAbdelkarimSalama, Mohamed Hassan Ibrahim, HodaFathyEbian, Hebatallah Husseini Atteia. Use of Enhanced liver fibrosis test (ELF) in Egyptian patients with chronic hepatitis C virus (HCV) infection to identify severity of liverfibrosis. International Journal of Advanced Research, 3(9), 2015; 384-390.
[2]. Alter MJ. Epidemiology of hepatitis C virus infection. World Journal of gastroenterology, 13(17), 2007; 2436-41.
[3]. Esposito I1, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Benítez-Gutiérrez L, Peña JM, Soriano V. Dual antiviral therapy for HIV andhepatitis C–drug interactions and side effects. Expert opinion on drug safety,14(9),2015; 1421-1434.
[4]. Ira M. Jacobson, M.D., Stuart C. Gordon, M.D., Kris V. Kowdley, M.D., Eric M. Yoshida, M.D., Maribel Rodriguez-Torres, M.D., Mark S. Sulkowski, M.D., Mitchell L. Shiffman, M.D., Eric Lawitz, M.D., Gregory Everson, M.D., Michael Bennett, M.D., Eugene Schiff, M.D., M. Tarek Al-Assi, M.D., G. Mani Subramanian, M.D., Ph.D., Di An, Ph.D., Ming Lin, Ph.D., John McNally, Ph.D., Diana Brainard, M.D., William T. Symonds, Pharm.D., John G. McHutchison, M.D., Keyur Patel, M.D., Jordan Feld, M.D., M.P.H., Stephen Pianko, M.D., Ph.D., and David R. Nelson, M.D. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England journal of medicine,368, 2013;1867-1877.
[5]. Michael J. Sofia, DonghuiBao, Wonsuk Chang, Jinfa Du, DhanapalanNagarathnam, SugunaRachakonda, P. Ganapati Reddy, Bruce S. Ross, Peiyuan Wang, Hai-Ren Zhang, Shalini Bansal, Christine Espiritu, Meg Keilman, Angela M. Lam, Holly M. MicolochickSteuer, CongrongNiu, Michael J. Otto, and Phillip A. Furman. Discovery of a beta-d-2′-deoxy-2′-alfafluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 53(19), 2010;7202–7218